SCHEMBL14867980

SCHEMBL14867980

CCCc1nc(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C(=O)CN5CCOCC5)CC4)ccc3OC)nn12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 19/20 0.65
PDE1A P54750 6/20 0.65
PDE1B Q01064 6/20 0.65
PDE1C Q14123 6/20 0.65
PDE4B Q07343 2/20 0.65
PDE6A P16499 2/20 0.65
PDE3B Q13370 2/20 0.65
PDE3A Q14432 2/20 0.65
PDE2A O00408 1/20 0.65
PDE6D O43924 1/20 0.65
PDE9A O76083 1/20 0.65
CHRM2 P08172 1/20 0.65
ADORA3 P0DMS8 1/20 0.65
PDE6G P18545 1/20 0.65
MAOA P21397 1/20 0.65
PDE4A P27815 1/20 0.65
ADORA1 P30542 1/20 0.65
ADRA1A P35348 1/20 0.65
PDE6B P35913 1/20 0.65
PDE6C P51160 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8218806 0.94 PDE5A (0.75) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL8210518 0.91 PDE5A (0.77) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL8220364 0.88 PDE5A (0.66) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL8211499 0.88 PDE5A (0.67) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL13011402 0.86 PDE5A (0.79) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL13694 0.86 PDE5A (0.87) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL8218692 0.85 PDE5A (0.85) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL8259092 0.83 PDE5A (0.84) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL973387 0.83 PDE5A (0.75) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL13825 0.83 PDE5A (0.73) PDE5APDE1APDE1BPDE1CPDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853394-B2 Pharmacokinetically improved compounds SURFACE LOGIX, INC. (US) 2014-10-07 US disclosed
US-8853394-B2 Pharmacokinetically improved compounds SURFACE LOGIX, INC. (US) 2014-10-07 US disclosed
US-20130096114-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX, INC. (US) 2013-04-18 US disclosed
US-20130096114-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX, INC. (US) 2013-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096114-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS ABCG2, SLC10A1, SLC10A2 PDE5A 1474/4885PDE1A 3065/4885PDE1B 3332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.